2021. August 3.
The invention relates to the field of assessing transport activity of OATP (Organic anion-transporting polypeptide) transport proteins. In particular, the invention relates to a real-time, add-and-read fluorescence-based method for determining whether a test compound interferes with substrate transport activity of an OATP, by using a non-fluorescent control substrate which becomes fluorescent within a cell. The method is also applicable to measure the expression of an OATP and to discriminate between a transported substrate and an inhibitor of an OATP.
2021. August 3.
The invention relates to the field of assessing transport activity of OATP (Organic anion-transporting polypeptide) and ABC (ATP Binding Cassette) transport proteins. In particular, the invention relates to methods for determining in a single, fluorescence-based assay whether a compound is a modulator of OATP and/or MRP2 (Multidrug resistance associated protein, ABCC) transport activity, using a fluorescent compound that is a substrate of both OATP and MRP2, and is selected from sulfopyrenes having general formula (I) or sulforhodamines having general formula (II).
2021. July 29.
The invention relates to a polymeric indicator fixed in a polymeric gel carrier, wherein the polymeric gel carrier comprises a hydrophilic polymer, wherein the polymeric indicator and the hydrophilic polymer are present together in the form of a combined cross-linked hydrogel network fixed by chemical bonds.
2021. July 9.
This invention relates to a biofilm carrier made of structured yarns (1) comprising filaments (2), where each individual filament (2) constituting the central yarn (1) forms a continuous fibre running over the entire length of the yarn (1) and filaments (2) are fixed to each other by anchor points (3) along the length of the yarn (1), and structured yarns (1) are fixed at fixing points (5) of a mesh structure (6), and each structured yarn (1) forms a loop (4) between two adjacent fixing points (5), the arc length (T) of which is greater than the distance (t) of the two fixing points (5).
2021. June 3.
The invention relates to a combined, solid, oral pharmaceutical composition that is usable for diminishing or protecting against the gastro-intestinal side effects of non-steroidal anti-inflammatory agents orally administered in a therapy, which contains capsaicinoid active agent in a small dose, one or more non-steroidal anti-inflammatory active agent, and one or more usual pharmaceutical auxiliary materials, characterized by that the composition comprises the active agent and other ingredients in a vehicle system which ensures the small concentration, uniform distribution and stability of the active agent on the mucous membrane.
